A Bioequivalence study of two Azithromycin tablet formulations in Indonesian healthy subjects

Yahdiana Harahap, Budi Prasaja, Windy Lusthom, Hardiyanti, Mena Bertony Ginting, Lipin

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To compare the bioavailability of two Azithromycin tablet formulations 500 mg Azivol® tablets as test formulation and 500 mg Zithromax® tablets as reference formulation. Methods: A single-dosed, open-label randomized two-way crossover design under fasting period with two weeks wash-out period was evaluated in 24 subjects. For the analysis of pharmacokinetic properties, the blood samples were drawn taken up to 120 hours after dosing. Plasma concentration of Azithromycin was determined using liquid chromatography - tandem mass spectrometry method with Turbolon Spray mode. Pharmacokinetic parameters AUC0-t, AUC0-∞ and Cmax were tested for bioequivalence after log-transformation of data and ratios of tmax were evaluated non-parametrically. Results: The point estimates and 90% confidence intervals (CI) for AUC0-t, AUC0-∞ and Cmax for Azithromycin were 94.63% (86.27-103.81%), 95.35% (87.15-104.31%), 94.16% (80.31-110.41%) respectively. Conclusion: These results indicated that the two formulations of Azithromycin were bioequivalent and thus may be prescribed interchangeably.

Original languageEnglish
Pages (from-to)48-51
Number of pages4
JournalJournal of Public Budgeting, Accounting and Financial Management
Volume24
Issue number2
DOIs
Publication statusPublished - 1 Jan 2012

Keywords

  • Antibiotic
  • Azithromycin
  • Bioequivalence and Bioavailability
  • LC-MS/MS

Fingerprint Dive into the research topics of 'A Bioequivalence study of two Azithromycin tablet formulations in Indonesian healthy subjects'. Together they form a unique fingerprint.

Cite this